+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Cilazapril with Adjunctive Hydrochlorothiazide


      S. Karger AG

      Cilazapril, Hypertension, Antihypertensive agents, Angiotensin-converting enzyme Inhibitors, Diuretics, Thiazide

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Experience is presented from clinical trials conducted during the development of cilazapril (CLZ) for the treatment of hypertension, in which hydrochlorothiazide (HCTZ) was added to the treatment regimen in patients whose blood pressures did not normalize [sitting diastolic blood pressure (SDBP) ≤ 90 mm Hg] in response to CLZ alone. In 906 mild-to-moderate hypertensives (SDBP = 95-114 mm Hg), adjunct therapy with 12.5-25 mg HCTZ added to 5 mg CLZ provided an additional 3-9 mm Hg reduction in SDBP and increased the normalization rate by 13-27%. Additional efficacy of the combination occurred without any compromise in safety (assessed in 1,189 mild-to-moderate and 99 severe hypertensives and in 9 normal healthy volunteers). Long-term treatment with CLZ and adjunctive HCTZ was well tolerated. The majority of clinical and laboratory adverse events were mild to moderate and not serious; only 5.7% of the mild-to-moderate hypertensives and 3.3% of the severe hypertensives withdrew from the studies due to adverse events and/or intercurrent illness. Therefore, given that the addition of HCTZ to CLZ appears to improve efficacy with no additional safety risk, combining CLZ with HCTZ appears to be a rational clinical choice for patients whose blood pressures do not normalize on CLZ monotherapy.

          Related collections

          Author and article information

          S. Karger AG
          18 November 2008
          : 86
          : 1
          : 41-48
          Hoffmann-La Roche, Nutley, N.J., USA
          176829 Cardiology 1995;86:41–48
          © 1995 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 8
          Clinical Pharmacology


          Comment on this article